PRAME anticorps (C-Term)
Aperçu rapide pour PRAME anticorps (C-Term) (ABIN2340213)
Antigène
Voir toutes PRAME AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Réactivité croisée
- Humain
-
Réactivité croisée (Details)
- Calculated cross reactivity: Hu
-
Attributs du produit
- PRAME, CT (Preferentially Expressed Antigen of Melanoma, Melanoma Antigen Preferentially Expressed in Tumors, MAPE, CT130, OPA Interacting Protein 4, OPA-interacting Protein 4, Opa-interacting Protein OIP4, OIP4)
-
Purification
- Purified by ammonium sulfate precipitation.
-
Immunogène
- Synthetic peptide selected from the C-terminal region of human MAPE (KLH).
-
Isotype
- IgG
-
-
-
-
Indications d'application
- Optimal working conditions should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Supplied as a liquid in PBS, 0.09 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- -20°C
-
-
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
-
Autre désignation
- PRAME
-
NCBI Accession
- NP_006106
-
UniProt
- P78395
-
Pathways
- Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding
Antigène
-